Biogen Inc
About
Biogen Inc (NASDAQ:BIIB) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
Apr 20 2026
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Mar 31 2026
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Mar 30 2026
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Mar 28 2026
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Financials
Revenue
$9.89 B
Market Cap
$26.03 B
P/E Ratio
20.15
EPS
8.80